Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 16, 2016 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Announces Qualified Infectious Disease Product (QIDP) Designation for MP-376, Inhaled Levofloxacin

Granted for Three Distinct Indications: Chronic Pulmonary Infections Due to Pseudomonas Aeruginosa in Patients with Cystic Fibrosis and in Patients with Non-Cystic Fibrosis Bronchiectasis as...
February 29, 2016 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Participate in International Rare Disease Week Through Multiple Patient Advocacy Activities

NOVATO, Calif., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its support of Rare Disease Week, beginning February 29, 2016, with a series of activities...
February 25, 2016 16:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Corp. Reports Fourth Quarter and Full Year 2015 Financial Results and Provides 2016 Corporate Update

2015 Global Net Revenue for PROCYSBI® of $94.2 Million Reported 2016 Global Net Revenue Guidance of $115 to $125 Million 2016 Anticipated PROCYSBI Growth of 25%-30% Year-Over Year Company to Host...
February 18, 2016 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25, 2016, at 4:30 p.m. ET

NOVATO, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release fourth quarter and full year 2015 financial results on...
January 25, 2016 07:05 ET | Source: Raptor Pharmaceutical Inc

Four New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan Exclusivity

Five Patents for PROCYSBI Now Listed in FDA Orange Book Orphan Drug Exclusivity Extended in Nephropathic Cystinosis Patients 2-6 Years Old NOVATO, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Raptor...
November 16, 2015 07:05 ET | Source: Raptor Pharmaceutical Inc

NIDDK Provides Additional Data From CyNCh Study Evaluating RP103 in Pediatric NASH at AASLD

NOVATO, Calif., Nov. 16, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (NASDAQ:RPTP) today announced researchers have provided additional results from the CyNCh study of RP103 for the treatment...
October 29, 2015 16:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Hold Third Quarter 2015 Financial Results Conference Call and Webcast on Thursday, November 5, 2015, at 4:30 p.m. ET

NOVATO, Calif., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release third quarter 2015 financial results on Thursday, November 5,...
October 05, 2015 07:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Completes Acquisition of Quinsair(TM)

NOVATO, Calif., Oct. 5, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has completed the acquisition of Quinsair™ (levofloxacin inhalation solution)...
September 23, 2015 07:30 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical to Participate in the Leerink Partners 4th Annual Rare Disease Roundtable

NOVATO, Calif., Sept. 23, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference: Julie Anne Smith,...
September 14, 2015 07:05 ET | Source: Raptor Pharmaceutical Inc

Raptor Pharmaceutical Provides Topline Results From Phase 2b CyNCh Study Evaluating RP103 in Pediatric Nonalcoholic Steatohepatitis

NOVATO, Calif., Sept. 14, 2015 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced topline results from the Phase 2b CyNCh study, which did not meet its primary endpoint of...